Amie Green
Nurse Practitioner · Rome, GANPI 1639520174
Payments from drug & device makers
Across 462 payments — averaging $25.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Sanofi$2K
- Regeneron Healthcare Solutions, Inc.$1K
- GSK$884
- Pfizer$764
- Amgen$574
- plus $4K from 33 others
What the payments were for
- Consulting fees$380%
- Food & beverage$11,63997%
- Education$2902%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 91 | $2,538 |
| Sanofi | 76 | $2,212 |
| Regeneron Healthcare Solutions, Inc. | 51 | $1,275 |
| GSK | 42 | $884 |
| Pfizer | 30 | $764 |
| Amgen | 19 | $574 |
| CSL Behring | 22 | $524 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $500 |
| Novartis | 19 | $428 |
| Galderma Laboratories, L.p. | 8 | $335 |
| Covis Pharma GmbH | 7 | $165 |
| Sanofi-aventis U.S. LLC | 2 | $156 |
| AbbVie | 8 | $146 |
| Alk-abello, Inc | 8 | $136 |
| Boehringer Ingelheim | 6 | $118 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $116 |
| Lilly USA, LLC | 5 | $113 |
| Optinose US, Inc. | 5 | $111 |
| Biocryst US Sales Co., LLC | 4 | $109 |
| Genentech USA, Inc. | 5 | $90 |
| Grifols USA, LLC | 4 | $84 |
| Kaleo, Inc. | 5 | $84 |
| Octapharma USA, Inc. | 1 | $68 |
| Blueprint Medicines Corporation | 2 | $62 |
| Organon | 2 | $44 |
| LEO Pharma Inc. | 2 | $39 |
| ADMA Biomanufacturing LLC | 1 | $38 |
| Greer Laboratories, Inc. | 1 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Insmed, Inc. | 1 | $29 |
| Ionis Pharmaceuticals, Inc. | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| USWM, LLC | 1 | $20 |
| Pharming Healthcare, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Arcutis Biotherapeutics, Inc. | 1 | $17 |
| Merck | 1 | $14 |
| Bio Products Laboratory USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,968 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 103 | $91,004 |
| FasenraBenralizumab | 12 | $79,105 |
| Advair HfaFluticasone Propion/Salmeterol | 37 | $22,334 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $22,140 |
| SymbicortBudesonide/Formoterol Fumarate | 60 | $16,285 |
| Spiriva RespimatTiotropium Bromide | 15 | $10,041 |
| Qvar RedihalerBeclomethasone Dipropionate | 21 | $9,162 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $8,646 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 47 | $8,265 |
| Azelastine Hcl | 218 | $7,768 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 37 | $7,493 |
| Ipratropium Bromide | 143 | $7,322 |
| Epinephrine | 24 | $4,219 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $3,870 |
| DuleraMometasone/Formoterol | 11 | $3,867 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $884 | $117,014146 claims |
| AstraZenecaFasenra, Symbicort | $2,538 | $95,39072 claims |
| Boehringer IngelheimSpiriva Respimat | $118 | $10,04115 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $31 | $9,16221 claims |
| Hikma Pharmaceuticals USAEpinephrine | $18 | $4,21924 claims |
| MerckDulera | $14 | $3,86711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Other nurse practitioner in Rome
- Pamela AllenRome$270K
- Tricia CollinsRome$17K
- Inga BennettRome$11K
- Crystal LogsdonSavannah$566K
- Victor CzerkasijDalton$505K
- Kennon Mc CollumStockbridge$364K
- Tajuana BradleyJohns Creek$256K
- Janice McAlisterAtlanta$241K
- Jessica AdkinsSavannah$226K
- Laura ElledgeAtlanta$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.